Infliximab Biosimilar Market Size, Share & Trends Analysis Report By Brand, Applications (Crohn’s disease, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, ankylosing spondylitis, plaque psoriasis, and others), Distribution Channel, Region And Segment Forecasts, 2025-2034

Report Id: 1060 Pages: 180 Last Updated: 18 June 2025 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Global Infliximab Biosimilar Market Segmentation

Infliximab Biosimilar Market By Brand

  • Avsola (infliximab-axxq)
  • Flixabi (SB2)
  • Inflectra (infliximab-dyyb)
  • Ixifi (infliximab-qbtx)
  • Remicade
  • Zessly
  • Infimab (BOW015)
  • NI-071
  • Infliximab BS
  • CMAB008
  • Others (Products approved in developing countries & pipeline products)

Infliximab Biosimilar Market By Application

  • Crohn’s Disease
  • Psoriatic Arthritis
  • Rheumatoid Arthritis
  • Ulcerative Colitis
  • Ankylosing Spondylitis
  • Plaque Psoriasis and others

Infliximab Biosimilar Market By Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Other Direct Distribution Channels

Infliximab Biosimilar Market By Region

Europe

  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • the Benelux
  • RoE 

North America:

  • United States
  • Canada

Asia Pacific:

  • India
  • Japan
  • South Korea
  • Australia

RoW

  • Brazil
  • South Africa
  • Turkey

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Infliximab Biosimilar Market Snapshot

Chapter 4. Global Infliximab Biosimilar Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2025-2034
4.8. Global Infliximab Biosimilar Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.10. Use/impact of AI on Infliximab Biosimilar Market Industry Trends

Chapter 5. Infliximab Biosimilar Market Segmentation 1: By Brand, Estimates & Trend Analysis
5.1. Market Share by Brand, 2024 & 2034
5.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Brand:

5.2.1. Avsola (infliximab-axxq)
5.2.2. Flixabi (SB2)
5.2.3. Inflectra (infliximab-dyyb)
5.2.4. Ixifi (infliximab-qbtx)
5.2.5. Remicade
5.2.6. Zessly
5.2.7. Infimab (BOW015)
5.2.8. NI-071
5.2.9. Infliximab BS
5.2.10. CMAB008
5.2.11. Others (Products approved in developing countries & pipeline products)

Chapter 6. Infliximab Biosimilar Market Segmentation 2: By Application, Estimates & Trend Analysis
6.1. Market Share by Application, 2024 & 2034
6.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Application:

6.2.1. Crohn’s Disease
6.2.2. Psoriatic Arthritis
6.2.3. Rheumatoid Arthritis
6.2.4. Ulcerative Colitis
6.2.5. Ankylosing Spondylitis
6.2.6. Plaque Psoriasis and others

Chapter 7. Infliximab Biosimilar Market Segmentation 3: By Distribution Channel, Estimates & Trend Analysis
7.1. Market Share by Distribution Channel, 2024 & 2034
7.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Distribution Channel:

7.2.1. Hospital Pharmacy
7.2.2. Online Pharmacy
7.2.3. Retail Pharmacy
7.2.4. Other Direct Distribution Channels

Chapter 8. Infliximab Biosimilar Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. Global Infliximab Biosimilar Market, Regional Snapshot 2024 & 2034
8.2. North America
8.2.1. North America Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
8.2.1.1. US
8.2.1.2. Canada
8.2.2. North America Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Brand, 2021-2034
8.2.3. North America Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.2.4. North America Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Distribution Channel, 2021-2034

8.3. Europe
8.3.1. Europe Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
8.3.1.1. Germany
8.3.1.2. U.K.
8.3.1.3. France
8.3.1.4. Italy
8.3.1.5. Spain
8.3.1.6. Rest of Europe
8.3.2. Europe Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Brand, 2021-2034
8.3.3. Europe Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.3.4. Europe Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Distribution Channel, 2021-2034

8.4. Asia Pacific
8.4.1. Asia Pacific Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
8.4.1.1. India
8.4.1.2. China
8.4.1.3. Japan
8.4.1.4. Australia
8.4.1.5. South Korea
8.4.1.6. Hong Kong
8.4.1.7. Southeast Asia
8.4.1.8. Rest of Asia Pacific
8.4.2. Asia Pacific Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Brand, 2021-2034
8.4.3. Asia Pacific Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.4.4. Asia Pacific Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Distribution Channel, 2021-2034

8.5. Latin America
8.5.1. Latin America Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
8.5.1.1. Brazil
8.5.1.2. Mexico
8.5.1.3. Rest of Latin America
8.5.2. Latin America Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Brand, 2021-2034
8.5.3. Latin America Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.5.4. Latin America Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Distribution Channel, 2021-2034

8.6. Middle East & Africa
8.6.1. Middle East & Africa Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by country, 2021-2034
8.6.1.1. GCC Countries
8.6.1.2. Israel
8.6.1.3. South Africa
8.6.1.4. Rest of Middle East and Africa
8.6.2. Middle East & Africa Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Brand, 2021-2034
8.6.3. Middle East & Africa Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.6.4. Middle East & Africa Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Distribution Channel, 2021-2034

Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances

9.2. Company Profiles

9.2.1. Amgen

9.2.1.1. Business Overview
9.2.1.2. Key Product/Service
9.2.1.3. Financial Performance
9.2.1.4. Geographical Presence
9.2.1.5. Recent Developments with Business Strategy

9.2.2. Samsung Bioepis
9.2.3. Celltrion
9.2.4. Pfizer
9.2.5. Johnson & Johnson
9.2.6. Sandoz (Novartis division)
9.2.7. Epirus Biopharmaceuticals
9.2.8. Nichi-Iko Pharmaceutical
9.2.9. Mabpharm
9.2.10. Biogen
9.2.11. Merck (MSD)
9.2.12. Ranbaxy Laboratories (now Sun Pharma)
9.2.13. Sorrento Therapeutics (partner)
9.2.14. Other Prominent Players

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
2716
Security Code field cannot be blank!

Frequently Asked Questions

Infliximab Biosimilar Market Size is valued at XX Million in 2024 and is predicted to reach XX Million by the year 2034

The Infliximab Biosimilar Market is expected to grow at an XX % CAGR during the forecast period for 2025-2034.

Napp Pharmaceuticals Group Ltd, Janssen Biotech Inc., Alvogen, Merck &Co. Inc., Celltrion Inc., Pfizer Inc. (ACAmgen, Samsung Bioepis, Celltrion, Pfiz

Brand, Applications, and Distribution Channel are the key segments of the Infliximab Biosimilar Market.

European region is leading the Infliximab Biosimilar Market.

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying